Se încarcă compania
Keep exploring
The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T USDA+
JNJJohnson & Johnson688,6B USDA+
MRKMerck & Co., Inc.364,3B USDA
NVSNovartis AG306,3B USDA
AMGNAmgen Inc.251,9B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Cum face bani
- Prescription medicines
- Vaccines
Concurează cu
Ce vinde5
Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.
Afișează încă 2
Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.
Cine cumpără3
- Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
- People receive Sanofi vaccines through healthcare providers and public health programs.
- Pharmacies and clinics are involved in medicine access programs.
Pe ce se sprijină și ce l-ar putea dărâma
De ce depinde activitatea
- 1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
- 2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
- 3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.
Ce ar putea merge prost
- 1Sanofi says its global business exposes it to increased risks in specific areas.
- 2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
- 3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.
Situațiile financiare complete →
Despre Sanofi
Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.
- Sediu
- Paris, France
- Înființată în
- 1973 (founding year, high)
- Listată la
- NYSE
- Sfârșitul exercițiului financiar
- December 31
Construit din raportările proprii ale Sanofi la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Această companie raportează în EUR. Cifrele sunt convertite în dolari la 1,00 USD = 0,904810 EUR, cursul actual, aplicat la fel tuturor perioadelor — astfel creșterea și marjele îi aparțin companiei, nu cursului valutar. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
